Document is current
Any future updates will be listed below
-
Authors
Lee, Chan
Eldridge, Matthew J. G. https://orcid.org/0000-0002-6538-4012
Gonzalez-Lozano, Miguel A. https://orcid.org/0000-0002-7837-151X
Bresnahan, Thomas
Niday, Zachary
Del Camino, Donato
Fu, Tao https://orcid.org/0000-0003-1783-2631
Paulo, Joao A. https://orcid.org/0000-0002-4291-413X
Moran, Magdalene M.
Helaine, Sophie https://orcid.org/0000-0002-9877-4180
Harper, J. Wade https://orcid.org/0000-0002-6944-7236
- License Information
-
More Information
Article History
Received: 4 October 2024
Accepted: 30 April 2025
First Online: 17 June 2025
Competing interests
: J.W.H. is a co-founder of Caraway Therapeutics, a subsidiary of Merck, and is a member of the scientific advisory board for Lyterian Therapeutics. T.B., Z.N., D.D.C. and M.M.M. participated in this study as employees of Caraway Therapeutics. The other authors declare no competing interests.
